113 related articles for article (PubMed ID: 24219061)
1. Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD.
Praschberger M; Cornelius C; Schitegg M; Goldenberg H; Scheiber-Mojdehkar B; Sturm B
Pharm Dev Technol; 2015 Mar; 20(2):176-82. PubMed ID: 24219061
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
[TBL] [Abstract][Full Text] [Related]
3. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator.
Stein J; Dignass A; Chow KU
Curr Med Res Opin; 2012 Feb; 28(2):241-3. PubMed ID: 22181342
[TBL] [Abstract][Full Text] [Related]
4. Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages.
Ternes N; Scheiber-Mojdehkar B; Landgraf G; Goldenberg H; Sturm B
Nephrol Dial Transplant; 2007 Oct; 22(10):2824-30. PubMed ID: 17556418
[TBL] [Abstract][Full Text] [Related]
5. Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity.
Praschberger M; Haider K; Cornelius C; Schitegg M; Sturm B; Goldenberg H; Scheiber-Mojdehkar B
Biometals; 2015 Feb; 28(1):35-50. PubMed ID: 25326244
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
7. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron.
Sturm B; Laggner H; Ternes N; Goldenberg H; Scheiber-Mojdehkar B
Kidney Int; 2005 Mar; 67(3):1161-70. PubMed ID: 15698458
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.
Barot BS; Parejiya PB; Mehta DM; Shelat PK; Shah GB
Pharm Dev Technol; 2014 Aug; 19(5):513-20. PubMed ID: 23701359
[TBL] [Abstract][Full Text] [Related]
10. [The application of intravenous iron Venofer in postpartum anemia syndrome or "a non-life-saving replaceable transfusion"].
Chalmanov N
Akush Ginekol (Sofiia); 2000; 39 Suppl 2():21-3. PubMed ID: 11188010
[No Abstract] [Full Text] [Related]
11. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.
Pai AB
Ann N Y Acad Sci; 2017 Nov; 1407(1):17-25. PubMed ID: 29027212
[TBL] [Abstract][Full Text] [Related]
12. Iron sucrose: assessing the similarity between the originator drug and its intended copies.
Di Francesco T; Philipp E; Borchard G
Ann N Y Acad Sci; 2017 Nov; 1407(1):63-74. PubMed ID: 29168243
[TBL] [Abstract][Full Text] [Related]
13. Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator.
Toblli JE; Cao G; Angerosa M
Biometals; 2015 Apr; 28(2):279-92. PubMed ID: 25609135
[TBL] [Abstract][Full Text] [Related]
14. Intravenous versus oral iron therapy for postpartum anaemia.
Bhandal N; Russell R
BJOG; 2006 Nov; 113(11):1248-52. PubMed ID: 17004982
[TBL] [Abstract][Full Text] [Related]
15. Sodium ferric gluconate (SFG) in complex with sucrose for IV infusion: bioequivalence of a new generic product with the branded product in healthy volunteers.
Baribeault D
Curr Med Res Opin; 2011 Aug; 27(8):1653-7. PubMed ID: 21714710
[TBL] [Abstract][Full Text] [Related]
16. [Intravenous treatment of postpartum anemia with trivalent ferrum preparation].
Binder T; Záhumenský J; Feldmár P; Dvorská M; Zmrhalová B
Ceska Gynekol; 2007 May; 72(3):169-74. PubMed ID: 17616069
[TBL] [Abstract][Full Text] [Related]
17. Short-term stability of a new generic sodium ferric gluconate in complex with sucrose.
Baribeault D
Curr Med Res Opin; 2011 Dec; 27(12):2241-3. PubMed ID: 21992082
[TBL] [Abstract][Full Text] [Related]
18. [Use of venofer for iron deficiency correction in patients undergoing programmed hemodialysis].
Fesiuk AF; Mordik AI; Borisova EV; Borisov AV; Lovchinskiĭ EV
Ter Arkh; 2003; 75(8):59-61. PubMed ID: 14520854
[TBL] [Abstract][Full Text] [Related]
19. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
[TBL] [Abstract][Full Text] [Related]
20. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial.
Kochhar PK; Kaundal A; Ghosh P
J Obstet Gynaecol Res; 2013 Feb; 39(2):504-10. PubMed ID: 22925176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]